Continuing Medical Education Program – Purchase Activities

Continuing Medical Education Program – Purchase Activities

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

   The Medical Letter Individual Activities — Online Only
I would like to order the following Per Issue Activities eligible for 2 credits each: $15 per activity
3 or more: $10/activity
1636 (2 credits)  Expires 10/20/2022
Atogepant (Qulipta) for Migraine Prevention
Empagliflozin (Jardiance) for Heart Failure with Reduced Ejection Fraction
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression
Apoaequorin (Prevagen) for Memory
1637 (2 credits)  Expires 11/03/2022
Drugs for Rheumatoid Arthritis
1638 (2 credits)
Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old
Booster Doses of COVID-19 Vaccines
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
Olanzapine/Samidorphan (Lybalvi) for Schizophrenia and Bipolar Disorder
1639 (2 credits)
Drugs for Alcohol Use Disorder
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
Abemaciclib (Verzenio) for Early Breast Cancer
1640 (2 credits)
Booster Doses of mRNA-Based COVID-19 Vaccines for All Adults
Clascoterone Cream (Winlevi) for Acne
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia
1641 (2 credits)
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
Antiviral Drugs for Influenza for 2021-2022
Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia
1642 (2 credits)
Paxlovid for Treatment of COVID-19
Molnupiravir for Treatment of COVID-19
Mifepristone by Mail for Pregnancy Termination
Ruxolitinib (Opzelura) for Atopic Dermatitis
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
COVID-19 Update
1643 (2 credits)
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
Drugs for Acute Otitis Media in Children
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
1644 (2 credits)
Tezepelumab (Tezspire) for Severe Asthma
Remimazolam (Byfavo) for Short-Term Procedural Sedation
Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
1645 (2 credits)
Nonopioid Drugs for Pain
1646 (2 credits)
An EUA for Bebtelovimab for Treatment of COVID-19
Inclisiran (Leqvio) for LDL-Cholesterol Lowering
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
COVID-19 Updates
1647 (2 credits)
Drugs for GERD and Peptic Ulcer Disease
1648 (2 credits)
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)
Tramadol/Celecoxib (Seglentis) for Pain
A Drug-Eluting Contact Lens for Allergic Conjunctivitis
Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose
Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
1649 (2 credits)
Drugs for Benign Prostatic Hyperplasia
Vazalore - A New Aspirin Formulation
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
1650 (2 credits)
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
1651 (2 credits)
Drugs and Devices for Weight Management
1652 (2 credits)
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
1653 (2 credits)
Drugs for Sexually Transmitted Infections
1654 (2 credits)
Tirzepatide (Mounjaro) for Type 2 Diabetes
Daridorexant (Quviviq) for Insomnia
COVID-19 Updates
1655 (2 credits)
Drugs for Treatment and Prevention of Venous Thromboembolism
1656 (2 credits)
COVID-19 Updates
Tapinarof Cream (Vtama) for Psoriasis
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
Lumateperone (Caplyta) for Bipolar Depression
1657 (2 credits)
Drugs for Cognitive Loss and Dementia
1658 (2 credits)
Prevention and Treatment of Monkeypox
Baricitinib (Olumiant) for Severe Alopecia Areata
Nalmefene Returns for Reversal of Opioid Overdose
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
1659 (2 credits)
Lipid-Lowering Drugs
1660 (2 credits)
Influenza Vaccine for 2022-2023
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
COVID-19 Update
1661 (2 credits)
Adult Immunization


ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

AAFP The AAFP has reviewed The Medical Letter Continuing Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2022 to 12/31/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 52 AAPA Category 1 CME credits. Approval is valid from 5/2/2021 to 12/31/2022 . PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202250.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hour(s) of knowledge-based continuing education credit (0.2 CEU).